Taking control of fibrotic diseases through targeted therapeutics
Certa Therapeutics
is developing innovative precision therapies for the treatment of fibrotic diseases
Certa’s story builds on more than two decades of scientific insight into a ‘master switch of fibrosis’ – GPR68.
Certa have developed a series of small molecule inhibitors of GPR68 with the aim of tackling fibrotic diseases upstream of other targeted biological pathways.
Certa has now brought together a consolidated portfolio of specific molecules which all target GPR68. They have been designed with characteristics to safely and effectively address different fibrotic conditions
Treatment of fibrosis is an unmet clinical need
Fibrotic diseases are an area of significant unmet need, responsible for an estimated 35.4% of all deaths globally.
Certa’s lead programme, FT011 (asengeprast), is being developed as a novel, first-in-class oral therapy for the treatment of systemic sclerosis (scleroderma) and has successfully completed a multi-national, phase II clinical trial. It has been awarded Orphan Drug Designation by the FDA and EMA for the treatment of scleroderma.
Further programs address major indications including chronic kidney disease, diabetic nephropathy and other chronic fibrotic indications.
A private company based in Melbourne Australia, Certa is backed by venture investors Brandon Capital and Uniseed
